Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD83 CAR T in Relapsed or Refractory AML
NCT06871410Phase 1Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Feb 2026
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD83 CAR T cells in acute myeloid leukemia (AML), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Incidence of dose-limiting toxicity at 28 days. Started Feb 2026; status: recruiting.
02
Drugs
CD83 CAR T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06871410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06871410.